{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:11:31Z","timestamp":1778821891028,"version":"3.51.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sepsis-induced myocardial injury (SIMI) is a major contributor to organ dysfunction and mortality in sepsis, driven primarily by excessive inflammation and mitochondrial dysfunction. Effective myocardial-targeted therapies remain limited. This study investigated the cardioprotective effects of Xiangdan injection in experimental sepsis induced by both Gram-positive and Gram-negative bacteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Sepsis was induced in male C57BL\/6 mice by intraperitoneal injection of\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (Gram-positive) or\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      (Gram-negative). Xiangdan injection was administered at doses of 2.0, 2.5, and 5.0 ml\/kg. Survival, myocardial histopathology, serum inflammatory cytokines, cardiac injury biomarkers, and mitochondrial ultrastructure were evaluated 12 h after sepsis induction. Mitochondrial damage was quantified using Flameng scoring.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Untreated sepsis significantly reduced survival (60% in Gram-positive and 70% in Gram-negative models) and caused severe myocardial injury. Xiangdan injection improved 12 h survival in a dose-dependent manner, achieving 100% survival at 5.0 ml\/kg in both models. Sepsis markedly increased serum IL-6 (102.7 \u00b1 13.6 pg\/ml), TNF-\u03b1 (98.5 \u00b1 12.5 pg\/ml), IL-1\u03b2 (68.1 \u00b1 8.9 pg\/ml), and HMGB1 (3.5 \u00b1 0.5 ng\/ml), which were significantly reduced by Xiangdan injection at 5.0 ml\/kg to 35.8 \u00b1 5.2 pg\/ml, 32.1 \u00b1 5.3 pg\/ml, 21.6 \u00b1 3.8 pg\/ml, and 1.1 \u00b1 0.2 ng\/ml, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.01). Cardiac injury biomarkers BNP, CK-MB, and cTnI were also significantly decreased (BNP: 172.5 \u00b1 22.1 to 62.2 \u00b1 10.3 pg\/ml; CK-MB: 398.7 \u00b1 45.2 to 147.3 \u00b1 19.4 U\/L; cTnI: 1.12 \u00b1 0.19 to 0.29 \u00b1 0.06 ng\/ml;\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.01). Mitochondrial ultrastructural damage was markedly attenuated, with Flameng scores reduced from 3.9 \u00b1 0.5 to 1.5 \u00b1 0.4 following high-dose Xiangdan treatment (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Xiangdan injection significantly attenuated the sepsis-induced myocardial injury by suppressing systemic inflammation, reducing cardiac injury, and preserving myocardial mitochondrial integrity in a dose-dependent and pathogen-independent manner.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1801630","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:29Z","timestamp":1778819309000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Xiangdan injection mitigates cardiac injury in experimental sepsis through inflammatory suppression and mitochondrial protection"],"prefix":"10.3389","volume":"13","author":[{"given":"Jingyu","family":"Xu","sequence":"first","affiliation":[{"name":"Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/epidemiologia5030032","article-title":"The global burden of sepsis and septic shock","volume":"5","author":"La Via","year":"2024","journal-title":"Epidemiologia (Basel)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2174\/157340311798220494","article-title":"Sepsis-induced cardiomyopathy","volume":"7","author":"Romero-Bermejo","year":"2011","journal-title":"Curr Cardiol Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.7150\/ijbs.111288","article-title":"Pathogenesis and treatment strategies of sepsis-induced myocardial injury: modern and traditional medical perspectives","volume":"21","author":"Yang","year":"2025","journal-title":"Int J Biol Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"15207","DOI":"10.2147\/JIR.S552730","article-title":"The role of mitochondrial dysfunction and inflammatory response in the pathogenesis of sepsis-induced myocardial injury: a mechanistic study","volume":"18","author":"Liu","year":"2025","journal-title":"J Inflamm Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"647785","DOI":"10.3389\/fcvm.2021.647785","article-title":"Post-ischemic myocardial inflammatory response: a complex and dynamic process susceptible to immunomodulatory therapies","volume":"8","author":"Pluijmert","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/pathogens13010089","article-title":"The impact of pathogens on sepsis prevalence and outcome","volume":"13","author":"Dyck","year":"2024","journal-title":"Pathogens."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/ijms25021082","article-title":"The role of pro-inflammatory cytokines in the pathogenesis of cardiovascular disease","volume":"25","author":"Zhang","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"118608","DOI":"10.1016\/j.biopha.2025.118608","article-title":"Immune cell dynamics and their role in cardiac injury: mechanisms and therapeutic implications","volume":"192","author":"Liu","year":"2025","journal-title":"Biomed Pharmacother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100524","DOI":"10.1016\/j.ahjo.2025.100524","article-title":"The current use of vasoactive agents in cardiogenic shock related to myocardial infarction and acute decompensated heart failure","volume":"52","author":"Becerra","year":"2025","journal-title":"Am Heart J Plus."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e860","DOI":"10.1002\/iid3.860","article-title":"Inflammatory mechanisms and intervention strategies for sepsis-induced myocardial dysfunction","volume":"11","author":"Nong","year":"2023","journal-title":"Immun Inflamm Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13054-025-05441-4","article-title":"Traditional Chinese medicine for sepsis: advancing from evidence to innovative drug discovery","volume":"29","author":"Ji","year":"2025","journal-title":"Crit Care."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1365639","DOI":"10.3389\/fphar.2024.1365639","article-title":"Mechanism and therapeutic potential of traditional Chinese medicine extracts in sepsis","volume":"15","author":"Fu","year":"2024","journal-title":"Front Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fphar.2016.00469","article-title":"Chinese herbal medicine on cardiovascular diseases and the mechanisms of action","volume":"7","author":"Liu","year":"2016","journal-title":"Front Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1669474","DOI":"10.3389\/fmed.2025.1669474","article-title":"Attenuation of sepsis-induced myocardial injury by Xiangdan injection via mitochondrial protection and inflammation suppression in mice","volume":"12","author":"Chang","year":"2025","journal-title":"Front Med (Lausanne)."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1643048","DOI":"10.3389\/fimmu.2025.1643048","article-title":"Combatting sepsis-induced myocardial dysfunction: emerging mechanisms and immunomodulatory breakthroughs","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.yjmcc.2024.08.003","article-title":"Mechanisms of the septic heart: from inflammatory response to myocardial edema","volume":"195","author":"Fan","year":"2024","journal-title":"J Mol Cell Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/jcdd11070206","article-title":"Systematic review on the role of IL-6 and IL-1\u03b2 in cardiovascular Diseases","volume":"11","author":"Katkenov","year":"2024","journal-title":"J Cardiovasc Dev Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"8210","DOI":"10.3390\/ijms26178210","article-title":"Atrial myopathy and heart failure: immunomolecular mechanisms and clinical implications","volume":"26","author":"Gil Fern\u00e1ndez","year":"2025","journal-title":"Int J Mol Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.18632\/aging.204990","article-title":"Xuebijing injection protects sepsis induced myocardial injury by mediating TLR4\/NF-\u03baB\/IKK\u03b1 and JAK2\/STAT3 signaling pathways","volume":"15","author":"Kang","year":"2023","journal-title":"Aging (Albany NY)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40635-025-00728-w","article-title":"Sepsis-induced cardiac dysfunction: mitochondria and energy metabolism","volume":"13","author":"Yu","year":"2025","journal-title":"Intensive Care Med Exp."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/cells14201621","article-title":"Advances in mitochondrial dysfunction and its role in cardiovascular diseases","volume":"14","author":"Qiu","year":"2025","journal-title":"Cells."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/ijms26051917","article-title":"Mitochondrial dysfunction in cardiovascular diseases","volume":"26","author":"Yang","year":"2025","journal-title":"Int J Mol Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.3390\/ijms25094710","article-title":"Current perspectives of mitochondria in sepsis-induced cardiomyopathy","volume":"25","author":"Kuroshima","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s10238-025-01842-5","article-title":"From cardiac injury to omics signatures","volume":"25","author":"Guarino","year":"2025","journal-title":"Clin Exp Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3390\/ijms26073218","article-title":"Cardiovascular biomarkers: tools for precision diagnosis and prognosis","volume":"26","author":"Netala","year":"2025","journal-title":"Int J Mol Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4137\/BMI.S12703","article-title":"Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management","volume":"8","author":"Kossaify","year":"2013","journal-title":"Biomark Insights"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0305920","DOI":"10.1371\/journal.pone.0305920","article-title":"Transcriptional markers classifying Escherichia coli and Staphylococcus aureus induced sepsis in adults: a data-driven approach","volume":"19","author":"Irani Shemirani","year":"2024","journal-title":"PLoS ONE."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1801630\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:30Z","timestamp":1778819310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1801630\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":27,"alternative-id":["10.3389\/fmed.2026.1801630"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1801630","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1801630"}}